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Introduction {#ehf212361-sec-0004}
============

Amyloidosis is a systemic disease caused by the extracellular deposition of misfolded protein fibrils, leading to progressive organ dysfunction.[1](#ehf212361-bib-0001){ref-type="ref"} Transthyretin (TTR) is a major amyloidogenic protein that forms a homotetramer and acts as a plasma transport protein for thyroid hormones and retinol‐binding protein with vitamin A. In patients with transthyretin amyloidosis (ATTR), amyloid fibrils, consisting of TTR monomers, dissociate from destabilized TTR tetramers. Depending on the presence or absence of a genetic mutation, ATTR is classified into two types: mutant ATTR (ATTRm) amyloidosis and wild‐type ATTR.[2](#ehf212361-bib-0002){ref-type="ref"}, [3](#ehf212361-bib-0003){ref-type="ref"}

Mutant ATTR was once believed to be a rare autosomal dominant disease, restricted to an endemic presence in specific areas; however, with the progression of molecular and biochemical analyses, it has become clear that this disease occurs worldwide. Although the Val30Met mutation is most prevalent type of mutation in ATTRm amyloidosis in Japan, many other TTR mutations exist.[4](#ehf212361-bib-0004){ref-type="ref"} To date, over 140 TTR mutations have been identified,[5](#ehf212361-bib-0005){ref-type="ref"} with ATTRm amyloidosis symptoms varying according to the TTR mutation.[6](#ehf212361-bib-0006){ref-type="ref"} ATTR symptoms are linked to the deposition of amyloid fibrils in several organs, for example, sensorimotor polyneuropathy, gastrointestinal tract disorders, and heart and kidney failure.[7](#ehf212361-bib-0007){ref-type="ref"}, [8](#ehf212361-bib-0008){ref-type="ref"}, [9](#ehf212361-bib-0009){ref-type="ref"}, [10](#ehf212361-bib-0010){ref-type="ref"} In particular, cardiac involvement causes heart failure and cardiac arrhythmias due to infiltrative and restrictive cardiomyopathy and impacts the prognosis of patients with ATTR.[8](#ehf212361-bib-0008){ref-type="ref"}, [9](#ehf212361-bib-0009){ref-type="ref"}, [10](#ehf212361-bib-0010){ref-type="ref"}, [11](#ehf212361-bib-0011){ref-type="ref"}

Because TTR‐derived amyloid fibril deposition causes peripheral and autonomic polyneuropathy, it is reasonable to speculate that the cardiac neuronal homeostasis is altered in patients with ATTRm amyloidosis. A reduced heart‐to‐mediastinum uptake (HM) ratio on 123‐iodine metaiodobenzylguanidine (^123^I‐MIBG) imaging, which is a noninvasive tool for assessing cardiac sympathetic nerve activity, has been reported to predict a poor prognosis in patients with ATTRm amyloidosis.[12](#ehf212361-bib-0012){ref-type="ref"} However, these previous reports did not evaluate cardiac events, such as worsening heart failure and/or the implantation of cardiac devices. In addition, these previous studies were conducted in western countries, and racial differences in cardiac phenotypes were not evaluated. Therefore, in the present study, we investigated the prognosis and predictors of clinical outcomes in patients with ATTRm amyloidosis in Japan.

Methods {#ehf212361-sec-0005}
=======

Study population {#ehf212361-sec-0006}
----------------

We retrospectively reviewed 95 consecutive patients with ATTRm amyloidosis who visited the Department of Neurology at Kumamoto University Hospital between July 1994 and April 2017. ATTRm amyloidosis was diagnosed by the observation of both amyloid fibril deposition on tissue biopsy (abdominal subcutaneous adipose tissue, skin, or gastrointestinal tract) and a TTR mutation on sequential analysis.[13](#ehf212361-bib-0013){ref-type="ref"} Patient characteristics, clinical evaluations, and clinical outcomes were analysed. Three patients were excluded because a pacemaker had already been implanted at the time of the diagnosis of ATTRm amyloidosis, and two patients were lost to follow‐up. Finally, we evaluated 90 patients with ATTRm amyloidosis. The study was conducted in accordance with the principles outlined in the Declaration of Helsinki, and the study protocol was approved by the Human Ethics Review Committee of Kumamoto University (no. 1324).

Cardiovascular evaluations {#ehf212361-sec-0007}
--------------------------

Electrocardiography (ECG), echocardiography, and laboratory data at the time of the diagnosis were collected. Echocardiography was performed using commercially available ultrasound equipment. Cardiac involvement was defined by increased wall thickness \[interventricular septum thickness in diastole (IVSTd) ≥ 12 mm\] on echocardiography in the absence of any other cause of ventricular hypertrophy.[7](#ehf212361-bib-0007){ref-type="ref"}, [14](#ehf212361-bib-0014){ref-type="ref"} The left ventricular ejection fraction (LVEF) was calculated using the modified Simpson\'s method. Early (E) and late atrial (A) transmitral peak flow velocities were measured from the mitral inflow velocities. The peak early diastolic velocity on the septal corner of the mitral annulus (e\') was determined by pulsed‐wave tissue Doppler imaging, and the E/e\' was calculated. Among the included patients, B‐type natriuretic peptide (BNP) was measured in 69 patients.

A total of 61 patients underwent ^123^I‐MIBG imaging at diagnosis, starting in 2009. We excluded two patients because of lost to follow‐up. Finally, we evaluated 59 patients. Anterior planar images were obtained at 15 min (early images) and 3 h (delayed images) after the intravenous injection of 111 MBq (3 mCi) of ^123^I‐MIBG (FUJIFILM RI Pharma Co., Ltd., Tokyo, Japan). The images were acquired with a dual‐headed gamma camera equipped with a low--medium energy general purpose collimator (Symbia T16, Siemens, CO., Ltd., Berlin, Germany). The image acquisition time was 5 min, matrix size was 256 × 256, zoom was 1.23, and the energy window was set at 159 keV (±7.5%). The pixel size was 1.95 mm. Using the region of interest (ROI) method, we calculated the early and delayed HM ratios on anterior views of the planar images. An irregular circular ROI was manually drawn on the left ventricle, and a square ROI was placed in the upper mediastinum area. The standardization of the HM ratio reported by Nakajima *et al*.[15](#ehf212361-bib-0015){ref-type="ref"}, [16](#ehf212361-bib-0016){ref-type="ref"} was used, and early and delayed HM ratios, and the washout rate, were calculated. The HM ratio was considered to be reduced if it was below 1.60 based on previous studies.[12](#ehf212361-bib-0012){ref-type="ref"}

Clinical follow‐up {#ehf212361-sec-0008}
------------------

We evaluated the incidence of a composite endpoint, defined as all‐cause death; hospitalization due to worsening heart failure; and implantation of a cardiac resynchronization therapy defibrillator (CRT‐D), implantable cardioverter defibrillator (ICD), or pacemaker due to a second‐degree or third‐degree atrioventricular block and sick sinus syndrome with symptoms. An ICD was implanted for primary prevention after a multidisciplinary team assessed the fatal ventricular arrhythmia risk if the patient had non‐sustained ventricular tachycardia. A CRT‐D was implanted based on the current European Society of Cardiology guidelines.[17](#ehf212361-bib-0017){ref-type="ref"}, [18](#ehf212361-bib-0018){ref-type="ref"} Mortality and cardiovascular events were identified by a search of the medical records, and were confirmed by a questionnaire and direct contact via a telephone interview of the patient or a family member, if deceased.

Statistical analysis {#ehf212361-sec-0009}
--------------------

Normally distributed data are presented as means ± standard deviation or medians (interquartile range), and group differences were evaluated using the Student\'s *t*‐test or Mann--Whitney *U*‐test. Categorical values are presented as numbers (percentage), and group differences were evaluated using the χ^2^ or Fisher\'s exact test, as appropriate. Variables with a skewed distribution were first logarithmically transformed prior to univariate linear regression analyses. Univariate Cox hazard analyses were performed to identify parameters significantly related to the composite endpoint. A multivariate Cox hazard analysis was performed using a forward stepwise model (*P* \< 0.10 for entry and *P* \< 0.05 to remain). Because the BNP level and delayed HM ratio had some missing values, we did not enter these factors into the multivariate model. Kaplan--Meier curves for the composite endpoint were constructed, and group differences were evaluated using the log‐rank test. A two‐tailed *P* value of 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 23 software (IBM Corp., Armonk, NY).

Results {#ehf212361-sec-0010}
=======

Patient characteristics and clinical outcomes {#ehf212361-sec-0011}
---------------------------------------------

*Table* [1](#ehf212361-tbl-0001){ref-type="table"} shows the patient characteristics for the total study population. During a median follow‐up period of 6.0 ± 6.3 years, the composite endpoint occurred in 23 patients (25.6%; event group). Details of the composite endpoint are as follows: all‐cause death (*n* = 6), hospitalization for worsening heart failure (*n* = 1), and implantation of an ICD (*n* = 6), CRT‐D (*n* = 3), or pacemaker (*n* = 7). All of the patients who had symptomatic bradyarrhythmia had pacemaker implantation. The 5‐year incident rate of clinical outcomes was 19%. An LVEF \< 50% was observed in only nine patients (10%). An IVSTd \> 12 mm was observed in 44 patients (49%). The median BNP level was 99.6 pg/mL, and a BNP level \> 100 pg/mL was observed in 15 patients (17%). In addition, the proportions of the observed ATTR gene mutations are shown in *Figure* [*1*](#ehf212361-fig-0001){ref-type="fig"}. A total of 67 patients (74.4%) had the Val30Met mutation, and many other known ATTR mutations in Japan were observed. Among the patients with the Val30Met mutation, 35 patients were classified as early onset (defined as a disease onset at or before 50 years of age). A total of 42 patients (47%) underwent ^99m^Tc‐labelled pyrophosphate scintigraphy. Among these, 21 patients had a left ventricular (LV) wall thickness \> 12 mm, approximately 90% of whom (*n* = 19) were positive for ^99m^Tc‐pyrophosphate scintigraphy.

###### 

Patient characteristics in the total study population according to the clinical outcome

                               All patients, *n* = 90   Event (−), *n* = 67    Event (+), *n* = 23    *P* value
  ---------------------------- ------------------------ ---------------------- ---------------------- -----------
  Age (year)                   56.7 ± 14.1              53.1 ± 14.0            67.3 ± 7.9             \<0.001
  Male (yes, %)                50 (55.6)                34 (50.7)              16 (69.6)              0.117
  Val30Met (yes, %)            67 (74.4)                53 (79.1)              14 (60.9)              0.084
  Age of onset (year)          49.3 ± 15.9              45.2 ± 15.7            60.9 ± 9.3             \<0.001
  PQ interval (ms)             184.9 ± 44.6             177.5 ± 46.2           205.4 ± 32.6           0.020
  QRS duration (ms)            104.7 ± 23.8             99.5 ± 19.0            118.8 ± 30.0           0.032
  LVDd (mm)                    41.4 ± 4.9               41.5 ± 4.6             40.9 ± 5.7             0.222
  LVDs (mm)                    26.4 ± 4.9               25.8 ± 5.0             28.1 ± 4.4             0.056
  IVSTd (mm)                   12.6 ± 3.9               11.4 ± 3.5             16.0 ± 3.1             \<0.001
  PWTd (mm)                    12.2 ± 3.6               10.8 ± 2.8             15.8 ± 2.9             \<0.001
  LVEF (%)                     61.6 ± 8.1               62.8 ± 8.1             58.1 ± 7.5             \<0.001
  E/A                          1.3 ± 0.8                1.4 ± 0.8              1.2 ± 0.8              0.071
  E/e\'                        13.9 ± 7.0               12.4 ± 6.3             18.2 ± 6.8             \<0.001
  Albumin (mg/dL)              4.0 ± 0.5                4.0 ± 0.5              3.9 ± 0.4              0.462
  Creatinine (mg/dL)           0.7 ± 0.2                0.7 ± 0.2              0.8 ± 0.2              0.032
  eGFR (mL/min/1.73 m^2^)      87.8 ± 26.3              92.7 ± 27.2            75.0 ± 18.7            0.007
  Haemoglobin (g/dL)           12.9 ± 1.16              13.0 ± 1.2             12.9 ± 1.1             0.667
  BNP (pg/mL) (*n* = 69)       99.2 (55.4--93.4)        79.1 (38.8--75.8)      142.0 (71.5--157.0)    \<0.001
  hs‐cTnT (ng/mL) (*n* = 52)   0.028 (0.022--0.038)     0.030 (0.028--0.043)   0.020 (0.017--0.025)   0.171

  ^123^I‐MIBG imaging    All patients, *n* = 59   Event (−) *n* = 41   Event (+) *n* = 18   *P* value
  ---------------------- ------------------------ -------------------- -------------------- -----------
  Age (years)            59.0 ± 15.1              54.9 ± 16.0          68.3 ± 6.5           0.003
  Male (*n*, %)          38 (64.4)                24 (58.5)            14 (77.8)            0.155
  Val30Met (*n*, %)      44 (74.6)                34 (82.9)            10 (55.6)            0.026
  Age of onset (years)   53.3 ± 15.7              48.9 ± 16.6          63.3 ± 6.0           0.004
  PQ interval (ms)       190.8 ± 38.0             181.1 ± 37.1         211.8 ± 31.4         0.003
  QRS duration (ms)      105.5 ± 22.8             98.7 ± 15.7          120.6 ± 28.7         0.014
  IVSTd (mm)             12.9 ± 3.8               11.4 ± 3.1           16.2 ± 3.2           \<0.001
  LVEF (%)               61.0 ± 8.0               62.7 ± 7.8           57.2 ± 7.3           0.004
  E/e\'                  13.5 ± 6.5               11.5 ± 5.3           18.2 ± 6.6           \<0.001
  BNP (pg/mL)            54.6 (35.4--78.3)        39.0 (18.9--73.6)    66.1 (56.7--116.5)   0.030
  Early HM ratio         2.3 ± 0.6                2.4 ± 0.6            2.1 ± 0.7            0.052
  Delayed HM ratio       2.1 ± 0.8                2.2 ± 0.8            1.7 ± 0.8            0.022
  Washout ratio          49.7 ± 33.1              44.6 ± 14.2          61.4 ± 55.3          0.270

BNP, B‐type natriuretic peptide; eGFR, estimated glomerular filtration rate; hs‐cTnT, high‐sensitivity cardiac troponin T; HM, ^123^I‐MIBG heart‐to‐mediastinum uptake; IVSTd, intraventricular septal thickness in diastole; LVDd, left ventricular diastolic dimension; LVDs, left ventricular systolic dimension; LVEF, left ventricular ejection fraction; PWTd, posterior wall thickness in diastole; ^123^I‐MIBG, 123‐iodine metaiodobenzylguanidine.

Data are presented as mean ± standard deviation, *n* (%), or median (interquartile range).

![*TTR* mutations observed in the present study.](EHF2-6-122-g001){#ehf212361-fig-0001}

Age and the age at onset were significantly older in the event group compared with those in the event‐free group (age: *P* \< 0.001; age at onset: *P* \< 0.001). On ECG, the event group had a longer PQ interval and QRS duration compared with those in the event‐free group (PQ interval: *P* = 0.020; QRS duration: *P* = 0.032). On echocardiography, the event group had significantly increased LV wall thickening and E/e\', and significantly worse LVEF, compared with those in the event‐free group (IVSTd: *P* \< 0.001; E/e\': *P* \< 0.001; LVEF: *P* \< 0.001). In addition, BNP levels were higher in the event group compared with those in the event‐free group (*P* \< 0.001). Almost all patients (*n* = 87) were treated by anti‐amyloid therapy; 49 patients were treated by tafamidis, five patients were treated by other anti‐amyloid drugs (diflunisal), and 33 patients underwent liver transplantation. The patients treated by tafamidis had the highest clinical event rate \[tafamidis, *n* = 17 (34.7%); liver transplantation, *n* = 41 (12.1%)\], as the patients who were treated by tafamidis were unable to undergo liver transplantation because of advanced age (tafamidis vs. liver transplantation: 60.6 ± 14.2 vs. 48.2 ± 9.6 years old, *P* \< 0.01) or organ failure, including heart failure.

Prognostic factors in mutant transthyretin amyloidosis {#ehf212361-sec-0012}
------------------------------------------------------

*Table* [2](#ehf212361-tbl-0002){ref-type="table"} shows the results of the univariate and multivariate Cox hazard analyses for the composite endpoint. In the multivariate analysis, age \[hazard ratio (HR): 1.07, 95% confidence interval (CI): 1.01--1.12, *P* = 0.015\], non‐Val30Met mutation (HR: 4.31, 95% CI: 1.53--12.16, *P* = 0.006), PQ interval (HR: 1.01, 95% CI: 1.00--1.02, *P* = 0.042), and IVSTd (HR: 1.25, 95% CI: 1.09--1.42, *P* = 0.001) were independently associated with the composite endpoint. *Figure* [*2*](#ehf212361-fig-0002){ref-type="fig"} shows the Kaplan--Meier curve for the probability of the composite endpoint among all study participants. In addition, the participants were divided into groups according to TTR mutation (Val30Met vs. non‐Val30Met) and IVSTd (≤12 vs. \>12 mm). The Kaplan--Meier analysis demonstrated a significantly higher probability of the composite endpoint in the non‐Val30Met group compared with that in the Val30Met group (log‐rank test: *P* = 0.002) and in patients with LV hypertrophy, defined as an IVSTd ≥ 12 mm, compared with that in patients without LV hypertrophy (log‐rank test: *P* \< 0.001) (*Figure* [*3*](#ehf212361-fig-0003){ref-type="fig"} *A* and *B*).

###### 

Results of univariate and multivariate Cox hazard analyses of clinical outcome predictors in the total study population

  Variables                     Univariate    Multivariate                                        
  ----------------------------- ------------ -------------- -------- -------------- ------------- -------
  Age (years)                   1.08           1.14--1.12   \<0.01        1.07       1.01--1.12   0.015
  Male (yes)                    2.16           0.88--5.28   0.093     Not selected                
  Non‐Val30Met mutation (yes)   3.23           1.38--8.02   0.012         4.31       1.53--12.16  0.006
  PQ interval (ms)              1.01           1.00--1.02   \<0.01        1.01       1.00--1.02   0.042
  QRS duration (ms)             1.03           1.01--1.04   \<0.01    Not selected                
  IVSTd (mm)                    1.32           1.19--1.47   \<0.01        1.25       1.09--1.42   0.001
  LVEF (%)                      0.94           0.90--0.98   \<0.01    Not selected                
  E/e\'                         1.07           1.02--1.13   0.004     Not selected                
  Creatinine (mg/dL)            8.96          1.42--56.79   0.020     Not selected                
  Ln BNP (*n* = 69)             2.62           1.14--6.00   0.023                                 
  Ln hs‐cTnT (*n* = 52)         5.42           0.99--29.7   0.052                                 
  Delayed HM ratio \<1.6        4.98          1.73--14.37   0.003                                 

CI, confidence interval; HR, hazard ratio; hs‐cTnT, high‐sensitivity cardiac troponin T; IVSTd, intraventricular septal thickness in diastole; Ln, log‐transformed; LVEF, left ventricular ejection fraction.

![Kaplan--Meier curve depicting the probability of clinical outcomes in all patients with mutant transthyretin amyloidosis.](EHF2-6-122-g002){#ehf212361-fig-0002}

![Kaplan--Meier curves depicting the probability of clinical outcomes in subgroups based on (A) *TTR* mutation, (B) left ventricular hypertrophy, and (C) delayed heart‐to‐mediastinum (HM) ratio. IVSTd, intraventricular septal thickness in diastole.](EHF2-6-122-g003){#ehf212361-fig-0003}

Among the 67 patients with the Val30Met mutation, the composite endpoint occurred in 14 patients (21%). Univariate Cox hazard analyses of the composite endpoint among patients with Val30Met mutation revealed the same tendencies as those in the analysis of all study participants; age, QRS duration, IVSTd, E/e\', and circulation levels of creatinine were significant predictors of the composite endpoint among Val30Met patients (data not shown).

Furthermore, we performed additional analyses on a limited endpoint that excluded device implantation (all‐cause death and hospitalization for worsening heart failure). This endpoint occurred in 12 patients (13%) (all‐cause death, *n* = 8; hospitalization for worsening heart failure, *n* = 4). The 5‐year event‐free rate was 86.9%. Univariate cox hazard analyses revealed the following predictors of this limited endpoint as follows: age, male sex, non‐Val30Met mutation, IVSTd, LVEF, E/e\', and the levels of creatinine, estimated glomerular filtration rate, and high‐sensitivity cardiac troponin T. We could not perform a multivariate analysis because of the low incidence of this limited endpoint (data not shown).

Prognostic utility of ^123^I‐MIBG scintigraphy {#ehf212361-sec-0013}
----------------------------------------------

The characteristics of the 59 patients who underwent ^123^I‐MIBG scintigraphy are shown in *Table* [1](#ehf212361-tbl-0001){ref-type="table"}. As in the analysis of the total study population, age and age at onset were significantly older in the event group compared with that in the event‐free group (age: *P* = 0.003; age at onset: *P* = 0.004). Non‐Val30Met mutation was more frequently observed in the event group than in the event‐free group (*P* = 0.026). On ECG, the event group had a longer PQ interval and QRS duration compared with those in the event‐free group (PQ interval: *P* = 0.003; QRS duration: *P* = 0.014). On echocardiography, the event group had significantly increased LV wall thickening and E/e\', and significantly worse LVEF, compared with those in the event‐free group (IVSTd: *P* \< 0.001; E/e\': *P* \< 0.001; LVEF: *P* = 0.004). BNP levels were higher in the event group compared with that in the event‐free group (*P* = 0.030). The average delayed HM ratio was 2.1 ± 0.8 across all patients with ^123^I‐MIBG scintigraphy data and was significantly lower in the event group compared with that in the event‐free group (1.7 ± 0.8 vs. 2.2 ± 0.8, *P* = 0.022).

The delayed HM ratio was significantly correlated with the LVEF and was significantly inversely correlated with age, IVSTd, E/e\', and the circulating BNP level in the univariate linear regression analyses (*Table* [3](#ehf212361-tbl-0003){ref-type="table"}; Supporting Information, *Figure* [*S1*](#ehf212361-supitem-0001){ref-type="supplementary-material"}). In the univariate Cox hazard analyses, a delayed HM ratio \< 1.6 was a significant predictive factor of the composite endpoint (HR: 4.98, 95% CI: 1.73--14.37, *P* = 0.003; Supporting Information, *Table* [*S1*](#ehf212361-supitem-0002){ref-type="supplementary-material"}). Kaplan--Meier curve analysis showed that a delayed HM ratio \< 1.6 is associated with a poor prognosis (log‐rank test: *P* = 0.001; *Figure* [*3*](#ehf212361-fig-0003){ref-type="fig"} *C*).

###### 

Result of the univariate linear regression analysis for the delayed HM ratio

  Factors              *r*      *P* value
  -------------------- -------- -----------
  Age (years)          −0.357   0.005
  PQ interval (ms)     −0.191   0.155
  QRS duration (ms)    −0.014   0.920
  LVEF (%)             0.336    0.009
  IVSTd (mm)           −0.562   \<0.001
  E/A                  0.217    0.116
  E/e\'                −0.426   0.001
  Creatinine (mg/dL)   −0.072   0.589
  Haemoglobin (g/dL)   0.139    0.297
  Ln BNP               −0.511   \<0.001

IVSTd, intraventricular septal thickness in diastole; Ln, log‐transformed; LVEF, left ventricular ejection fraction.

Discussion {#ehf212361-sec-0014}
==========

The major findings of the present study are as follows: (i) the 5‐year incident rate of clinical outcomes was 19% in patients with ATTRm amyloidosis in Japan; (ii) non‐Val30Met mutation and LV hypertrophy (IVSTd \> 12 mm) were significant predictive factors of clinical outcomes; and (iii) the delayed HM ratio was significantly correlated with LV wall thickness, and a low delayed HM ratio (\>1.6) was an independent predictor of poor clinical outcomes. Together, these results indicate that the type of genetic mutation, presence of LV hypertrophy, and delayed HM ratio are useful predictors of clinical outcomes in Japanese patients with ATTRm amyloidosis. To our knowledge, the present study is the first to demonstrate the incidence of cardiac events and prognostic factors, with a long follow‐up duration (median follow‐up period, 6.0 years), in patients with ATTRm amyloidosis in Japan.

Previous studies have shown that ^123^I‐MIBG imaging is useful in predicting a poor prognosis in patients with ATTRm amyloidosis. Although the endpoint of these previous studies was all‐cause death, the main cause of death was cachexia or surgical death. Other studies have analysed the prognostic utility of ^123^I‐MIBG imaging among patients with only Val30Met ATTRm amyloidosis.[12](#ehf212361-bib-0012){ref-type="ref"} Furthermore, Ruberg *et al*.[19](#ehf212361-bib-0019){ref-type="ref"} previously demonstrated that ATTRm amyloidosis with Val122Ile mutation is associated with worse morbidity and mortality, and a higher cardiovascular hospitalization rate, compared with those in wild‐type ATTR. However, this previous study had a very small sample size and was limited to the Val122Ile mutation. Furthermore, many studies of ATTRm amyloidosis have been conducted in Europe[11](#ehf212361-bib-0011){ref-type="ref"} or the USA,[20](#ehf212361-bib-0020){ref-type="ref"} which have different *TTR* mutation and phenotype patterns from those in Japan. Thus, there are no previous reports on the clinical outcomes (including cardiac events) and their predictors in a large number of Japanese patients with various *TTR* mutations in ATTRm amyloidosis. The present study is first to report on the prognosis of patients with ATTRm amyloidosis in Japan. We believe that this study provides useful clinical information and can improve cardiac management, not only in Japanese patients with ATTRm amyloidosis but also in patients worldwide.

In the present study, 74% of patients had the Val30Met mutation. This mutation is found worldwide and is the most common *TTR* mutation in the world. Val30Met mutation, particularly in patients with early‐onset Val30Met ATTRm amyloidosis, is characterized by a predominant loss of superficial sensation. However, a previous study revealed that cardiomyopathy is observed in 43% of patients with Val30Met amyloidosis.[7](#ehf212361-bib-0007){ref-type="ref"} Consistent with this, cardiomyopathy, defined as an IVSTd \> 12 mm, was observed in 27 patients (40.3%) in the present study. Because cardiac amyloidosis is not rare in patients with the Val30Met mutation and LV hypertrophy is significantly correlated with cardiac events, it is important to evaluate the progression of cardiomyopathy via consecutive echocardiographic monitoring.

Left ventricular hypertrophy indicates the deposition of amyloid fibrils in the heart, based on a morphological evaluation of cardiac amyloidosis. We additionally evaluated cardiac denervation using ^123^I‐MIBG imaging. In the present study, the delayed HM ratio was inversely correlated with the IVSTd, and a low delayed HM ratio was associated with a high clinical event rate. In a pioneering study on patients with Val30Met amyloidosis using ^123^I‐MIBG imaging, Tanaka *et al*.[21](#ehf212361-bib-0021){ref-type="ref"} demonstrated that cardiac denervation might occur before LV wall thickening or clinically apparent heart disease. In addition, several studies have demonstrated that the delayed HM ratio correlates negatively with the severity of polyneuropathy.[22](#ehf212361-bib-0022){ref-type="ref"}, [23](#ehf212361-bib-0023){ref-type="ref"} This observation suggests that cardiac denervation is present prior to cardiac hypertrophy. Thus, ^123^I‐MIBG imaging should be considered if advanced polyneuropathy manifests, even if LV hypertrophy is not observed, to evaluate the cardiac involvement.

Recently, new drugs for ATTRm amyloidosis therapy have been developed, such as those for TTR stabilization (diflunisal[24](#ehf212361-bib-0024){ref-type="ref"} and tafamidis[25](#ehf212361-bib-0025){ref-type="ref"}) and the suppression of TTR production (siRNA[26](#ehf212361-bib-0026){ref-type="ref"}), improving the neuropathic prognosis of patients with ATTRm amyloidosis. Although these therapies are expected to decrease cardiac events, a prior study showed an absence of significant changes in biochemical and echocardiographic parameters with tafamidis therapy for ATTR‐related cardiomyopathy.[27](#ehf212361-bib-0027){ref-type="ref"} As LV hypertrophy and cardiac denervation were revealed to be useful predictive factors of clinical outcomes in the present study, the evaluation of these parameters using reproducible methods, such as cardiac magnetic resonance imaging and ^123^I‐MIBG, may act as reliable surrogate makers for clinical outcomes in determining the efficacy of new TTR drugs. However, further evaluation is necessary to confirm this point.

The present study has several limitations to acknowledge. First, ATTRm amyloidosis is a rare disease, even in our endemic area; thus, the sample size was relatively small. Second, we defined the composite endpoint as all‐cause mortality, hospitalization for heart failure, and device implantation, including an ICD for primary prevention. The indication of an ICD for primary prevention in patients with ATTRm amyloidosis is still controversial. As mentioned previously, a multidisciplinary team assessment of the risk of fatal ventricular arrhythmia was performed if the patient had non‐sustained ventricular tachycardia. Unfortunately, we could not evaluate the incidence of appropriate ICD discharges because we did not follow‐up all of the patients with an ICD/CRT‐D at our institution. It is necessary to evaluate the risk stratification of future fatal ventricular tachycardia and the appropriate ICD implantation criteria in patients with ATTRm amyloidosis in further studies. Third, there are some biases inherent to observational studies. ^123^I‐MIBG scintigraphy scanning depended on the judgement of the physicians and was obtained in only 59 patients. Therefore, we could not include these parameters in the multivariate analysis of the cardiac prognostic factors in ATTRm amyloidosis. Finally, the study design was retrospective in nature. Further prospective studies of larger groups are needed to confirm the present results.

In conclusion, the present results indicate that non‐Val30Met mutation, the presence of LV hypertrophy, and a low delayed HM ratio are useful predictive factors of clinical outcomes in patients with ATTRm amyloidosis in Japan. These results suggest that it is important to evaluate cardiac involvement in terms of morphological (LV hypertrophy) and functional (cardiac denervation) perspectives using echocardiography and ^123^I‐MIBG imaging, respectively.
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**Figure S1.** The scatterplots show the relationship between the delayed HM ratio in ^123^I‐MIBG scintigraphy and (A) age, (B) LVEF, (C) IVSTd, (D) E/e', and (E) Ln BNP, as assessed in linear regression analyses.

^123^I‐MIBG: 123‐iodine metaiodobenzylguanidine, HM: ^123^I‐MIBG heart‐to‐mediastinum uptake, LVEF: left ventricular ejection fraction, IVSTd: intraventricular septal thickness in diastole, Ln BNP: log‐transformed B‐type natriuretic peptide.
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**Table S1.** Results of the univariate Cox hazard analyses for clinical outcome predictors in patients who underwent ^123^I‐MIBG imaging (*n*=59).

###### 

Click here for additional data file.

###### 

Supporting info item

###### 

Click here for additional data file.
